Literature DB >> 31204706

Genetic variant rs10937405 of TP63 and susceptibility to lung cancer risk in north Indian population.

G H Rasool Bhat1, Amrita Bhat, Sonali Verma, Itty Sethi, Ruchi Shah, Varun Sharma, S Minerva, Divya Bakshi, Bhanu Sharma, Sandeep Koul, Deepak Abrol, Audesh Bhat, Rakesh Kumar.   

Abstract

Several studies including genomewide association studies (GWASs) in diverse ethnic populations have reported a significant association of genetic variant rs10937405 of TP63 with nonsmall cell lung cancer (NSCLC). However, no data are available from any Indian population on the association of this variant with NSCLC. Using TaqMan genotyping chemistry, we conducted a case-control study involving 190 NSCLC cases and 400 ethnic, age-matched controls to explore the association of rs10937405 genetic variant with NSCLC in patients from north India. Our data support that the rs10937405 variant is also significantly associated with the NSCLC and is a risk factor in the north Indian populations to develop NSCLC. However, unlike most other studies, the wild-type allele T appears to be the risk allele, as its frequency was significantly higher in the cases than controls (0.439 in cases versus 0.383 in controls. OR=1.95 (1.23-3.09 at 95% CI); P value (adjusted)= 0.004). Genetic association was also observed by applying different genetic models. The present study provides important information of the genetic aetiology of NSCLC and strengthens GWAS findings, highlighting the role of TP63 in lung cancer risk.

Entities:  

Year:  2019        PMID: 31204706

Source DB:  PubMed          Journal:  J Genet        ISSN: 0022-1333            Impact factor:   1.166


  1 in total

1.  Polymorphism in the TP63 gene imparts a potential risk for leukemia in the North Indian population.

Authors:  Amrita Bhat; Gh Rasool Bhat; Sonali Verma; Ruchi Shah; Ashna Nagpal; Bhanu Sharma; Divya Bakshi; Jyotsna Suri; Supinder Singh; Mukesh Tanwar; Samantha Vaishnavi; Audesh Bhat; Rakesh Kumar
Journal:  Afr Health Sci       Date:  2021-09       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.